Rituximab vs. Cyclophosphamide induction therapy for patients with ANCA-associated vasculitis

Authors

Sheng Chen (ORCID: https://orcid.org/0000-0001-7428-7153)
Wenyi Wu (ORCID: https://orcid.org/0000-0002-4958-8760)
Juan Wang (ORCID: https://orcid.org/0000-0003-0767-5687)

Institutions

Shanghai Jiao Tong University (CN)
Renji Hospital (CN)

Publication Details

Journal: BMC Rheumatology
Published: 2025-11-28
DOI: https://doi.org/10.1186/s41927-025-00597-6
Primary Topic: Vasculitis and related conditions
Type: article
Field-Weighted Citation Impact: 0.00

Funders

National Natural Science Foundation of China

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Rituximab vs. Cyclophosphamide induction therapy for patients with ANCA-associated vasculitis

Sheng Chen, Wenyi Wu, Juan Wang

Nov 28, 2025

BMC Rheumatology

Vasculitis and related conditions

article

Rituximab vs. Cyclophosphamide induction therapy for patients with ANCA-associated vasculitis

Sheng Chen, Wenyi Wu, Juan Wang

November 28, 2025article en

Abstract

No abstract available for this paper.

BMC RheumatologyVol. 9(1)

Shanghai Jiao Tong University (CN), Renji Hospital (CN)

National Natural Science Foundation of China

Openalex Percentile: Top 45%

Vasculitis and related conditions

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Rituximab vs. Cyclophosphamide induction therapy for patients with ANCA-associated vasculitis — Sheng Chen, Wenyi Wu, et al. · BMC Rheumatology (2025) | TGRS Research Map | TGRS